Cystic fibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc.

Cystic fibrosis therapies, such as TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others, are expected to boost the Cystic fibrosis Market in the upcoming years.

DelveInsight has launched a new report on "Cystic fibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cystic fibrosis, historical and forecasted epidemiology as well as the Cystic fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Cystic fibrosis market report @ https://www.delveinsight.com/report-store/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Cystic fibrosis Market Report:

In 2023, the Cystic Fibrosis market size across the 7MM was approximately USD 18.7 billion, with the United States contributing around USD 9.5 billion-the largest share among the regions. The U.S. alone accounted for about USD 7.05 billion in market size. The anticipated launch of new therapies and a growing prevalence of cystic fibrosis are expected to drive market expansion in the years ahead.
This rising prevalence is influenced by increased awareness, genetic predispositions, and healthcare policy changes. Since cystic fibrosis is a genetic disorder caused by CFTR gene mutations, factors such as higher rates of consanguinity may further contribute to its growth during the forecast period (2024-2034).
Although treatments like TRIKAFTA, SYMDEKO, and ORKAMBI (approved by the US FDA and developed by Vertex Pharmaceuticals) have shown benefits, they are not curative and may involve side effects. Combination therapies targeting multiple CFTR mutations are gaining traction for improved outcomes.
However, high treatment costs and the lack of mutation-specific personalized therapies may hinder market growth.
Despite these challenges, several therapies are being investigated for the Cystic Fibrosis therapies including Vertex Pharmaceutical's VX-121, Verona Pharmaceutical's Ensifentrine, and others for the management of cystic fibrosis in the 7MM.
According to DelveInsight's analysis, the diagnosed prevalence of Cystic Fibrosis in the 7MM was estimated at around 67,897 cases in 2023. Broader access to genetic testing is expected to help identify more individuals with the condition, contributing to a rise in reported cases. The United States accounted for the highest number of diagnosed cases among the 7MM, with approximately 33,391 cases in 2023, and this number is projected to grow over the forecast period (2024-2034).
In March 2025, ReCode Therapeutics received Orphan Drug Designation from the FDA for RCT2100, its experimental mRNA therapy for cystic fibrosis.
In February 2025, Porosome Therapeutics also secured FDA Orphan Drug Designation for its novel therapy targeting secretory defects in cystic fibrosis.
In January 2025, Lupin Limited announced tentative FDA approval for its generic version of Ivacaftor Oral Granules (25 mg, 50 mg, and 75 mg), a counterpart to Vertex's Kalydeco.
That same month, the FDA approved a new triple-combination CFTR modulator-vanzacaftor, tezacaftor, and deutivacaftor-developed by Vertex and branded as *Alyftrek*, for treating CF in patients aged 6 and older with at least one responsive mutation, including F508del.
Key Cystic fibrosis companies such as Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., and others are evaluating new drugs for Cystic fibrosis to improve the treatment landscape.
Promising Cystic fibrosis therapies include TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others.

Cystic fibrosis Overview

Cystic Fibrosis (CF) is a life-limiting, autosomal recessive genetic disorder caused by mutations in the CFTR gene, which encodes an ion channel protein located on chromosome 7. The condition leads to the buildup of thick, sticky mucus, primarily affecting the lungs and digestive system, resulting in chronic respiratory infections, digestive issues, and other complications.

Cystic fibrosis Market Outlook

Cystic fibrosis treatment involves a comprehensive, multidisciplinary strategy focused on symptom management, complication prevention, and enhancing quality of life. Due to respiratory difficulties and bronchospasms in CF patients, bronchodilators like albuterol (marketed as Ventolin), a selective beta2-adrenoceptor agonist, are commonly used to relax airway smooth muscles and ease breathing. Additional treatment components include airway clearance methods, mucus-thinning agents, antibiotics for lung infections, nutritional support, lung transplants for severe cases, and innovative gene-based treatments such as CFTR modulators.

The cystic fibrosis drug market is expected to expand as research progresses and new therapies are introduced. Key pharmaceutical companies actively developing CF treatments in the 7MM include Vertex Pharmaceuticals, Verona Pharma, and Eloxx Pharmaceuticals, among others. Growing research activity and upcoming therapeutic candidates signal a shift in the cystic fibrosis treatment landscape, with emerging therapies poised to offer significant advancements for patients.

Discover how the Cystic fibrosis market is rising in the coming years @ https://www.delveinsight.com/sample-request/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cystic fibrosis marketed drugs
TRIKAFTA: Vertex Pharmaceuticals
SYMDEKO: Vertex Pharmaceuticals
KALYDECO: Vertex Pharmaceuticals

Cystic fibrosis Emerging Drugs
VX-121/TEZ/ VX-561: Vertex Pharmaceuticals
Ensifentrine: Verona Pharmaceuticals

Scope of the Cystic fibrosis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cystic fibrosis Companies: Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., and others
Key Cystic fibrosis Therapies: TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others
Cystic fibrosis Therapeutic Assessment: Cystic fibrosis current marketed and Cystic fibrosis emerging therapies
Cystic fibrosis Market Dynamics: Cystic fibrosis market drivers and Cystic fibrosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Cystic fibrosis Unmet Needs, KOL's views, Analyst's views, Cystic fibrosis Market Access and Reimbursement

To know what's more in our Cystic fibrosis report, visit https://www.delveinsight.com/report-store/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Cystic fibrosis Market Report:
Cystic fibrosis market report covers a descriptive overview and comprehensive insight of the Cystic fibrosis Epidemiology and Cystic fibrosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Cystic fibrosis market report provides insights into the current and emerging therapies.
The Cystic fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Cystic fibrosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cystic fibrosis market.

Got queries? Click here to know more about the Cystic fibrosis market Landscape https://www.delveinsight.com/sample-request/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cystic fibrosis Patient Share (%) Overview at a Glance
5. Cystic fibrosis Market Overview at a Glance
6. Cystic fibrosis Disease Background and Overview
7. Cystic fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Cystic fibrosis
9. Cystic fibrosis Current Treatment and Medical Practices
10. Unmet Needs
11. Cystic fibrosis Emerging Therapies
12. Cystic fibrosis Market Outlook
13. Country-Wise Cystic fibrosis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cystic fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Cystic fibrosis Market Outlook 2034 https://www.delveinsight.com/report-store/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Cystic fibrosis Pipeline Insights, DelveInsight

"Cystic fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cystic fibrosis market. A detailed picture of the Cystic fibrosis pipeline landscape is provided, which includes the disease overview and Cystic fibrosis treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.